Featured Articles

  1. A Sponsor's Guide To Evaluating CRO Data Governance 7/30/2026

    Evaluate CRO data governance with a risk-based framework that strengthens data quality, traceability, compliance, and regulatory readiness.

  2. Interpreting Early Inflammation Signals: What Early Human Data Tells Us 7/10/2026

    Early inflammatory signals can mislead without context. Benchmarked human challenge models reveal true biological activity, guiding decisions on mechanism, dosing, and clinical development.

  3. Why Benchmarking Inflammatory Models Matters: What Early Human Data Tells Us 7/6/2026

    Benchmarking immune challenge models clarifies early pharmacodynamic signals, helping teams distinguish true target engagement from variability, prioritize endpoints, and make confident decisions.

  4. Expression Of Key Immunology Drug Targets In Human Inflammatory Challenge Models 7/6/2026

    Human challenge models reveal immune pathway behavior in controlled settings, linking early research to outcomes and helping confirm target engagement, refine dosing, and reduce development uncertainty.

  5. How Pharmacometrics Informs Dose Selection And Biomarker Decisions 6/10/2026

    Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

  6. Why Early Clinical Development Is Shifting Toward Decision-Enabling Study Designs 6/9/2026

    Early clinical research is shifting to decision-focused designs, using biomarkers, functional endpoints, and targeted populations to reduce uncertainty and enable clearer progression.

  7. Why AI Matters In Early Phase Clinical Trials 3/11/2026

    AI speeds early‑phase development by streamlining data review, enabling structured queries, accelerating PK/PD work, and revealing biomarker patterns — boosting efficiency with expert oversight.

  8. Accelerating Parkinson's Disease Clinical Research Through Recruitment Capabilities 1/14/2026

    Centralized PD trials cut variability, speed enrollment, and enable genetic stratification, delivering high‑quality data and faster progress from early‑phase research to late‑stage development.

  9. Navigating The Enrollment Bottleneck In Early Oncology Trials 1/12/2026

    Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

  10. 6 Key Implications Of EU Clinical Trials Regulation 1/7/2026

    Centralized submissions, greater transparency, and stronger patient protections reshape EU clinical trials, impacting timelines, costs, and strategies for sponsors and CROs.